Processa Pharmaceuticals, Inc. (PCSA)

NASDAQ: PCSA · IEX Real-Time Price · USD
1.89
0.21 (12.50%)
May 17, 2022 3:59 PM EDT - Market closed
Market Cap29.94M
Revenue (ttm)n/a
Net Income (ttm)-12.56M
Shares Out15.84M
EPS (ttm)-0.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume61,439
Open1.68
Previous Close1.68
Day's Range1.50 - 1.93
52-Week Range1.50 - 8.99
Beta-0.20
AnalystsBuy
Price Target15.30 (+709.5%)
Earnings DateMay 12, 2022

About PCSA

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatme...

IndustryBiotechnology
Founded2011
Employees15
Stock ExchangeNASDAQ
Ticker SymbolPCSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for PCSA stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 709.52% from the latest price.

Price Target
$15.3
(709.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

HANOVER, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical ...

5 days ago - GlobeNewsWire

Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Nex...

Processa f ocuse s on i dentify ing the PCS6422 regimens to i ncrease c apecitabine potency while identifying the MTD of Next Generation Capecitabine

3 weeks ago - GlobeNewsWire

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastrop...

HANOVER, MD, April 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve th...

1 month ago - GlobeNewsWire

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update

Targeting Major Milestones 2022

1 month ago - GlobeNewsWire

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development ...

HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of li...

1 month ago - GlobeNewsWire

Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference

HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve th...

2 months ago - GlobeNewsWire

Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022

HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical...

3 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update

Clinical D rug P ipeline is F unded and T argeting M ajor M ilestones mid-2022

6 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DP...

HANOVER, MD, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the...

6 months ago - GlobeNewsWire

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Upda...

HANOVER, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the...

6 months ago - GlobeNewsWire

Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis

HANOVER, MD, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the...

7 months ago - GlobeNewsWire

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update

HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve th...

8 months ago - GlobeNewsWire

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve th...

8 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27

HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of lif...

8 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update

Adds fourth clinical asset, RX-3117, and target s major milestones in the second half of 2021

9 months ago - GlobeNewsWire

Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Upd...

HANOVER, Md., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of li...

9 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET

HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event on ...

9 months ago - GlobeNewsWire

4 Stocks With CEO Buys in the Past Month

According to the CEO Buys Screen, a Premium All-in-One Screener template, four stocks that had at least three insider buys including the CEO during the past month are REV Group Inc. ( REVG , Financial),...

Other symbols:CMTREVGVINC
10 months ago - GuruFocus

Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET

HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation will b...

10 months ago - GlobeNewsWire

Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent

Processa Pharmaceuticals Inc (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ: OCUP) to in-license RX-3117. RX-3117 is an oral anticancer agent with an improved pha...

Other symbols:OCUP
11 months ago - Benzinga

PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117

HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to l...

11 months ago - GlobeNewsWire

Processa Set to Join Russell Microcap® Index

HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the...

11 months ago - GlobeNewsWire

Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET

HANOVER, MD, June 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the...

11 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Tr...

~ Processa's trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica . Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562 .~

11 months ago - GlobeNewsWire

Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update

Clinical drug pipeline is funded and targeting major milestones in Q2 and 2H 2021

1 year ago - GlobeNewsWire